Table 1.
Total adverse event, cardiac adverse event, and atrial fibrillation events reported with different glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors group of drugs
| Drug | Total adverse events | Cardiac adverse events | Atrial fibrillation | Percentage of AF out of total AE |
|---|---|---|---|---|
| DPP-4i | 12 872 | 1357 | 100 | 0.77 |
| Sitagliptin | 8371 | 528 | 48 | 0.57 |
| Saxagliptin | 1138 | 468 | 12 | 1.05 |
| Linagliptin | 3363 | 361 | 40 | 1.18 |
| GLP-1 RA | 75 264 | 1964 | 208 | 0.27 |
| Dulaglutide | 38 972 | 792 | 81 | 0.20 |
| Exenatide | 17 335 | 443 | 52 | 0.29 |
| Liraglutide | 9829 | 431 | 75 | 0.76 |
| Semaglutide | 9128 | 298 | 39 | 0.42 |
| SGLT-2i | 34 008 | 1914 | 142 | 0.41 |
| Canagliflozin | 12 051 | 578 | 37 | 0.31 |
| Empagliflozin | 16 690 | 930 | 79 | 0.47 |
| Dapagliflozin | 5267 | 406 | 26 | 0.49 |
| Metformin | 46 320 | 4447 | 208 | 0.44 |
| Sulfonylureas | 5627 | 479 | 30 | 0.53 |
AE, adverse events; DPP-4i, dipeptidyl peptidase-4 inhibitors; GLP-1 RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2 inhibitors.